Listed

Enveric Biosciences, Inc.: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Apr 1, 2021 and accepted by EDGAR at Apr 1, 2021, 17:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2020-01-01 to 2020-12-31$174.1kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2020-01-01 to 2020-12-31$5.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2020-01-01 to 2020-12-31−$5.6mus-gaap:OperatingIncomeLoss
Interest expense12 months2020-01-01 to 2020-12-31$445.3kus-gaap:InterestExpense
Net income12 months2020-01-01 to 2020-12-31−$6.9mus-gaap:NetIncomeLoss
Diluted EPS12 months2020-01-01 to 2020-12-31−$1.19us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2020-01-01 to 2020-12-31−$3.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-12-31$1.6mus-gaap:Cash
Current assetsAt period end2020-12-31$2.3mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$4.1mus-gaap:Assets
Total liabilitiesAt period end2020-12-31$681.3kus-gaap:Liabilities
Shareholders' equityAt period end2020-12-31$3.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-21-007757. Last ingested by Listed: Nov 14, 2026, 20:02 ET. Listed shows no prices and gives no investment advice.